120017
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
温敏栓塞剂 TACE 联合 HAIC 及靶向/免疫治疗不可切除原发性肝癌的临床疗效探索
Authors Chen X , Xiao H , Lan X, Du C
Received 18 October 2025
Accepted for publication 5 February 2026
Published 13 February 2026 Volume 2026:13 572484
DOI https://doi.org/10.2147/JHC.S572484
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Mohamed Shaker
Xingyu Chen,* Heng Xiao,* Xiang Lan, Chengyou Du
Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Xiang Lan, Department of Hepatobiliary Surgery, The First Hospital of Chongqing Medical University, No. 1 Youyi Road, Yuanjiagang, Yuzhong District, Chongqing, 400016, People’s Republic of China, Tel +86-023-89011191, Email lanxiang_tmmu@163.com Chengyou Du, Department of Hepatobiliary Surgery, The First Hospital of Chongqing Medical University, No. 1 Youyi Road, Yuanjiagang, Yuzhong District, Chongqing, 400016, People’s Republic of China, +86-023-89011192, Email duchengyou@126.com
Objective: To evaluate the efficacy and safety of TEM-TACE combined with HAIC and targeted/immunotherapy for the treatment of unresectable primary liver cancer, and to clarify the clinical application potential of this multimodal therapeutic regimen.
Methods: This study was a small-sample retrospective case series. The clinical data of 4 patients with unresectable primary liver cancer who underwent TEM-TACE combined with HAIC and targeted/immunotherapy in our hospital from April 2025 to July 2025 were retrospectively analyzed. Tumor response was evaluated according to the mRECIST criteria, and the occurrence of adverse reactions was assessed on the basis of the Clavien–Dindo classification system. All patients included in this study provided written informed consent for the publication of their clinical details.
Results: Among the 4 patients, 2 were diagnosed with HCC, and the other 2 were diagnosed with ICC. All 4 patients achieved a PR after treatment with TEM-TACE combined with HAIC and targeted/immunotherapy, with a mean tumor reduction of 42.3%. The ORR and DCR both reached 100%. Among these patients, 2 successfully achieved treatment conversion and underwent radical surgical resection, while the remaining 2 refused surgery for personal reasons. During the perioperative period, only Clavien–Dindo grade I–II complications (mainly abdominal pain and nausea) occurred in the 4 patients, which improved after symptomatic treatment, and no severe adverse reactions were observed.
Conclusion: The multimodal therapeutic regimen of TEM-TACE combined with HAIC and targeted/immunotherapy is safe and effective for unresectable primary liver cancer. In particular, compared with conventional embolic agents, temperature-sensitive embolic agents enable precise peripheral embolization and sustained drug release, thereby significantly reducing tumor volume and improving the rate of conversion to surgical resection. Moreover, this regimen provides a novel approach for the conversion therapy of unresectable ICC. It is suitable for patients with primary liver cancer who have a tumor diameter > 10 cm, liver function of Child-Pugh class A/B, and no severe comorbidities. However, further studies with larger sample sizes are still required to verify its long-term efficacy.
Keywords: unresectable primary liver cancer, temperature-sensitive embolic agent, transarterial chemoembolization, hepatic artery infusion chemotherapy, combined therapy
Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Xiang Lan, Department of Hepatobiliary Surgery, The First Hospital of Chongqing Medical University, No. 1 Youyi Road, Yuanjiagang, Yuzhong District, Chongqing, 400016, People’s Republic of China, Tel +86-023-89011191, Email lanxiang_tmmu@163.com Chengyou Du, Department of Hepatobiliary Surgery, The First Hospital of Chongqing Medical University, No. 1 Youyi Road, Yuanjiagang, Yuzhong District, Chongqing, 400016, People’s Republic of China, +86-023-89011192, Email duchengyou@126.com
Objective: To evaluate the efficacy and safety of TEM-TACE combined with HAIC and targeted/immunotherapy for the treatment of unresectable primary liver cancer, and to clarify the clinical application potential of this multimodal therapeutic regimen.
Methods: This study was a small-sample retrospective case series. The clinical data of 4 patients with unresectable primary liver cancer who underwent TEM-TACE combined with HAIC and targeted/immunotherapy in our hospital from April 2025 to July 2025 were retrospectively analyzed. Tumor response was evaluated according to the mRECIST criteria, and the occurrence of adverse reactions was assessed on the basis of the Clavien–Dindo classification system. All patients included in this study provided written informed consent for the publication of their clinical details.
Results: Among the 4 patients, 2 were diagnosed with HCC, and the other 2 were diagnosed with ICC. All 4 patients achieved a PR after treatment with TEM-TACE combined with HAIC and targeted/immunotherapy, with a mean tumor reduction of 42.3%. The ORR and DCR both reached 100%. Among these patients, 2 successfully achieved treatment conversion and underwent radical surgical resection, while the remaining 2 refused surgery for personal reasons. During the perioperative period, only Clavien–Dindo grade I–II complications (mainly abdominal pain and nausea) occurred in the 4 patients, which improved after symptomatic treatment, and no severe adverse reactions were observed.
Conclusion: The multimodal therapeutic regimen of TEM-TACE combined with HAIC and targeted/immunotherapy is safe and effective for unresectable primary liver cancer. In particular, compared with conventional embolic agents, temperature-sensitive embolic agents enable precise peripheral embolization and sustained drug release, thereby significantly reducing tumor volume and improving the rate of conversion to surgical resection. Moreover, this regimen provides a novel approach for the conversion therapy of unresectable ICC. It is suitable for patients with primary liver cancer who have a tumor diameter > 10 cm, liver function of Child-Pugh class A/B, and no severe comorbidities. However, further studies with larger sample sizes are still required to verify its long-term efficacy.
Keywords: unresectable primary liver cancer, temperature-sensitive embolic agent, transarterial chemoembolization, hepatic artery infusion chemotherapy, combined therapy